biocon biologics restructures deal with sii | nithya balasubramanian speaks on this & more
Published 1 year ago • 1.1K plays • Length 6:56Download video MP4
Download video MP3
Similar videos
-
11:46
sanford bernstein's nithya balasubramanian shares her views on biocon, gland pharma | cnbc-tv18
-
7:57
sanford bernstein's nithya balasubramanian on q4 results of pharma cos & china opportunity
-
6:50
biocon's kiran mazumdar shaw on strong q4, biosimilar business & fy24 outlook | halftime report
-
24:15
spotlight on biocon-serum deal, ipca's unichem acquisitions & mankind pharma's ipo | cnbc-tv18
-
4:33
biocon biologics's shreehas tambe speaks on us fda's observation | bazaar open exchange | cnbc-tv18
-
6:02
biocon malaysia overview
-
54:02
biocon biologics' management on acquiring biosimilars business of viatris
-
5:24
serum takes its investment in biocon bio to $300 million, kiran m shaw on this & more | cnbc-tv18
-
10:05
sanford bernstein's nithya balasubramanian's take on pharma universe | bazaar morning call
-
19:14
adar poonawalla on serum's $ 300 m investment in biocon biologics | trading hour | cnbc-tv18
-
3:05
biopharmaceutical company says it expects to reach profitability in 2025
-
8:03
expect to see some traction in biocon in h2; like gland pharma among injectables: sanford bernstein
-
1:23
local firm biosyngen opens cell manufacturing facility for immunotherapy
-
2:35
strong biosimilar growth powers biocon | trading hour | cnbc tv18
-
7:25
ethical considerations for generative ai | sriram natarajan | tedxwoodinville
-
7:26
biocon biologies ipo, debt reduction strategy & more | kiran mazumdar-shaw & peter bains